Veradermics, Inc (MANE) Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Veradermics, Incorporated NYSE:MANE Healthcare · Biotechnology
AH Close $138.78 +0.00% vs close
AH Close $138.78 +0.00% vs close
All Press Release SEC Filings News
Press Release ● Critical ⚠ 3
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
Veradermics' Phase 3 Study '304' met all primary and secondary endpoints for VDPHL01, an oral extended-release minoxidil for male pattern hair loss, in 536 participants with high statistical significance (p<0.0001).
Hair count gains reached 28.6 hairs/cm² (once daily) and 36.4 hairs/cm² (twice daily) versus 6.6 for placebo at Month 6, with onset of efficacy visible as early as Month 2 and no treatment-related serious adverse events or cardiac adverse events of special interest.
Combined with positive Study '302' data, the results support a potential NDA as the first FDA-approved non-hormonal oral treatment targeting 50 million U.S. men; female-pattern Study '306' topline is expected in the first half of 2027.
• 6d ago AI analysis › Press Release ⚠ 1
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics will host an investor call and webcast on October 19, 2026, at 8:00 am ET to review topline results from Part A of its Phase 3 Study '304' of VDPHL01 in over 500 males with mild-to-moderate pattern hair loss.
VDPHL01 is an extended-release oral minoxidil in a three-trial registration program enrolling more than 1,600 men and women; if approved, it would be the only FDA-approved oral non-hormonal treatment for pattern hair loss.
The call announcement flags a near-term binary readout for the clinical-stage company, though no efficacy or safety data are disclosed in this release.
• 7d ago AI analysis › Press Release
Veradermics to Present at Upcoming September Investor Conferences
Veradermics (NYSE: MANE), a dermatologist-founded late clinical-stage biopharmaceutical company focused on pattern hair loss therapies, announced management participation in three September investor conferences.
Management will hold investor meetings at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026 in Boston, present at Citi's 2026 Biopharma Back to School Conference on September 9 at 3:00 p.m. ET, and present at the 2026 Cantor Global Healthcare Conference on September 10 at 3:20 p.m. ET, both in New York. Live webcasts of the Citi and Cantor presentations will run on the company's IR site, with replays available for roughly 30 days.
The release contains no financial, regulatory, or pipeline news; its About section restates that lead program VDPHL01, an oral extended-release minoxidil tablet, is in Phase 3 development for pattern hair loss in women and men, and that the earliest expiring patent term is 2043.
• 1mo ago AI analysis › Press Release ● Major ⚠ 2
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics reported positive topline results from a Phase 2 study of VDPHL01 in female pattern hair loss, demonstrating rapid onset and consistent hair growth, and completed enrollment for its 556-patient registration-directed Phase 2/3 Study '306'.
The company strengthened its balance sheet with $819.9 million in cash and equivalents as of June 30, 2026, supported by a $472.0 million follow-on offering in May, which is expected to fund operations into 2030.
Q2 financial results showed a net loss of $23.5 million, compared to $15.6 million in the prior year, driven by increased R&D and G&A expenses related to clinical development and commercial readiness.
• 2mo ago AI analysis › Press Release
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
Veradermics presented new subgroup analysis data from Phase 2/3 Study 302 for VDPHL01 in male pattern hair loss at the American Academy of Dermatology Innovation Academy. The analysis evaluated efficacy and safety across age groups in over 500 males treated with the proprietary extended-release oral minoxidil formulation.
Topline results from Study 302 were initially announced in April 2026, while topline data from the second Phase 3 male trial, Study 304, are anticipated in the second half of 2026.
The company also confirmed that topline data from Study 306, a registration-directed Phase 2/3 trial in females, are expected in the first half of 2027.
• 3mo ago AI analysis › Press Release ● Major ⚠ 1
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
Veradermics reported positive Phase 2 results for oral VDPHL01 in female pattern hair loss, showing that approximately 90% of patients reported improved hair coverage at Month 6.
The drug achieved a mean increase in non-vellus hair count of 22.7 to 23.3 hairs/cm² and demonstrated a favorable safety profile with no treatment-related serious adverse events.
Management indicated these results strengthen conviction for the upcoming registration-directed Phase 2/3 Study '306', which is expected to report topline data in the first half of 2027.
• 3mo ago AI analysis › Press Release
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
Veradermics announced it will host a conference call on July 15, 2026, to review results from the female treatment arms of the Phase 2 Study '207' evaluating VDPHL01 for mild-to-moderate pattern hair loss.
VDPHL01 is a proprietary extended-release oral minoxidil tablet currently in Phase 3 development, designed to offer improved safety and efficacy while avoiding high peak concentrations.
The company estimates pattern hair loss affects 80 million people in the U.S. and represents a projected $30 billion market opportunity by 2028.
• 3mo ago AI analysis › Press Release
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Achieve Life Sciences appointed Jeffrey Farrow and Reid Waldman, MD to its Board of Directors to bolster commercial and strategic oversight ahead of its NDA resubmission for cytisinicline.
Farrow brings extensive late-stage launch experience, having served as CFO for three biopharma companies acquired for a combined $9 billion, including Global Blood Therapeutics and Hyperion Therapeutics.
Waldman, CEO of Veradermics (MANE), adds clinical and commercial expertise in dermatology and aesthetics, having led his company through a $294.8M IPO and subsequent $472M follow-on financing.
The appointments signal management’s focus on building a board with deep operational experience in navigating FDA approvals and commercial launches for specialty pharmaceuticals.
• 4mo ago AI analysis › Press Release
Veradermics to Present at Upcoming June Investor Conferences
Veradermics announced that CEO Reid Waldman and Chief Commercial Officer Mark Neumann will present at the Jefferies Global Healthcare Conference on June 3.
CEO Reid Waldman will also host a corporate presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8.
Live webcasts of both presentations will be available on the company’s investor relations website, with replays accessible for approximately 30 days.
• 4mo ago AI analysis › Press Release
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research
Veradermics will present positive topline results from its Phase 2/3 '302' study of VDPHL01 at the 2026 World Congress for Hair Research on May 30.
The data, originally shared in April, covers Part A of the randomized, double-blind, placebo-controlled trial involving over 500 males with mild-to-moderate pattern hair loss.
The company positions VDPHL01 as a potential first-in-class FDA-approved oral pill for pattern hair loss in nearly 30 years, targeting a $30 billion global aesthetics market.
• 4mo ago AI analysis › Press Release
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
Veradermics will present two E-posters on VDPHL01, its investigational extended-release oral minoxidil tablet, at the 2026 Music City SCALE Symposium in Nashville.
The first poster is a blinded, retrospective investigator global assessment comparing VDPHL01's efficacy in males at 2 and 4 months against 6-month data for immediate-release oral minoxidil and topical minoxidil.
The second poster uses the AI-based Global HairMap™ platform to compare androgenetic alopecia outcomes of VDPHL01 at 4 months against 6 months of immediate-release oral minoxidil treatment.
VDPHL01 is in Phase 3 development for pattern hair loss in both women and men, with the potential to be the first FDA-approved oral non-hormonal treatment for this condition.
• 5mo ago AI analysis › Press Release
Veradermics Announces Launch of Public Offering
Veradermics launched a proposed public offering of 3.35 million shares of common stock and pre-funded warrants, with underwriters granted a 30-day option to purchase an additional 502,500 shares.
A concurrent private placement of pre-funded warrants to affiliates of Suvretta Capital will occur on a one-for-one basis with the public offering, maintaining a total aggregate issuance of 3.35 million securities.
The offering is being led by Needham & Company with Jefferies, Leerink Partners, Citigroup, and Cantor Fitzgerald acting as joint book-running managers.
• 5mo ago AI analysis › Press Release ● Critical
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
Veradermics reported positive topline results from its Phase 2/3 trial of oral VDPHL01 in male pattern hair loss, with the drug meeting all primary and key secondary endpoints with high statistical significance.
Treatment with VDPHL01 resulted in robust hair growth, with increases of 30.3 and 33.0 hairs/cm² for once-daily and twice-daily dosing respectively, compared to 7.3 hairs/cm² for placebo at Month 6.
The company reported that 79.3% and 86.0% of patients saw improvement with once-daily and twice-daily dosing, respectively, versus 35.6% for placebo, with a favorable safety profile observed.
• 5mo ago AI analysis › Press Release
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302' Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
businesswire.com • 5mo ago 
